Advertisement

Fake medicine trade booming

AFP
AFP - [email protected]
Fake medicine trade booming
Photo: DPA

More than one in three Germans has bought prescription medicines without a doctor's script, according to a study released Tuesday that reveals the scope of Europe's counterfeit pharmaceutical trade.

Advertisement

The market in counterfeit medicines in Europe is worth an estimated €10.5 billion a year, the research commissioned by pharmaceutical giant Pfizer out Tuesday.

One in five of those questioned for the research admitted buying prescription-only medicines without a prescription, with people in Germany (38 percent) and Italy (37 percent) the worst offenders.

Italians and Germans are also thought to have spent the most on fake prescription-only medicines – an estimated €3.6 billion and €2.7 billion respectively.

The most popular kinds of medicines to buy are those related to weight loss (45 percent), flu (35 percent) and erectile dysfunction (25 percent), the research found.

It comes amid growing concern over the issue among officials who say fake medicines are often unsafe, inefficient or of poor quality.

In December, European industry commissioner Gunter Verheugen said the European Union had seized 34 million fake tablets in just two months, a figure which "exceeded our worst fears."

An EU report from July last year claimed that many of the fake pharmaceuticals seized in 2008 came from India.

But the World Health Organisation says it is hard to calculate the extent of counterfeiting of medicines.

Research consultancy Nunwood questioned 14,000 people in 14 European countries online in November for the Pfizer research. The €10.5 billion figure was calculated based on the number of people buying prescription-only medication without a prescription, multiplied by the average annual spend per purchaser.

More

Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.

Please log in to leave a comment.

See Also